kabutan

Kringle Pharma, Net Income Forecast for the Fiscal Year Loss to Narrow

Wed Mar 11, 2026 2:15 pm JST Revision

4884 Kringle Pharma,Inc. 【J-GAAP】

Guidance Update Report

Kringle Pharma,Inc. <4884> [TSE Growth] announced a performance revision in the afternoon session on March 11th (14:15). The net income/loss (non-consolidated) forecast for the fiscal year ending September 2026 has been revised upward from an expected loss of 1.17 billion yen to a loss of 1.02 billion yen (compared to a loss of 0.91 billion yen in the previous period), indicating a reduction in the loss margin.

Furthermore, The company continued to decline to disclose its earnings forecast for October to March (first half).

Kabutan News

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Sep, 2026 Prev 72 -1,172 -1,172 -1,173 -159.6 0 Nov 12, 2025 J-GAAP
Sep, 2026 New 332 -1,018 -1,018 -1,020 -138.8 0 Mar 11, 2026 J-GAAP
Revision Rate +361.1% +13.1% +13.1% +13.0% +13.0%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 35 -511 -511 -512 -75.2 0 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance ー ー ー ー － 0 Nov 12, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Sep, 2024 80 -817 -754 -756 -118.2 0 Nov 13, 2024 J-GAAP
Sep, 2025 72 -909 -914 -916 -133.9 0 Nov 12, 2025 J-GAAP
Sep, 2026 Guidance 332 -1,018 -1,018 -1,020 -138.8 0 Mar 11, 2026 J-GAAP
YoY +361.1% -12.0% -11.4% -11.4% -3.6%

Related Articles